GABY Inc. Announces Closing of Financing as It Marches Toward Completing Its Acquisition of Mankind Dispensary
Summary
"The closing of our Private Placement and the completion of the audit takes us a significant step closer to our expansion into the cannabis retail channel," said Margot Micallef, Founder, President and Chief Executive Officer of GABY. Each Warrant entitles the holder to purchase a GABY Share at an exercise price of C$0.09, at any time up to 24 months following the date of issuance, subject to the Acceleration Right.All securities issued in connection with the Private Placement are subject to a four month and one day hold period from the date of this press release in accordance with applicable securities laws.Based in Sonoma County California, GABY is a cannabis consumer goods company with proprietary cannabis brands sold in over 200 dispensaries throughout California. For more information on GABY, visit www.GABYInc.com.For investor inquiries, please contact: IR@GABYinc.com or 800-674-2239Completion of the Merger is subject to a number of conditions, including, but not limited to, the acceptance of the CSE and shareholder approval. Without limitation, these risks and uncertainties include: the parties being unable to obtain the required CSE and shareholder approvals; the severity of the COVID-19 pandemic; the failure to complete the Merger on satisfactory terms, risks associated with the cannabis industry in general, failure to benefit from partnerships or successfully integrate acquisitions, actions and initiatives of federal, state and provincial governments and changes to government policies and the execution and impact of these actions, initiatives and policies, the size of the medical-use and adult-use cannabis market, competition from other industry participants, adverse U.S., Canadian and global economic conditions, failure to comply with certain regulations and departure of key management personnel or inability to attract and retain talent. Any such proceedings brought against GABY, or its subsidiary may materially adversely affect the Companys operations and financial performance generally in the U.S. market specifically.Neither the CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.